ACAD
38.36
-0.54
-1.39%
AEMD
0.196
-0.01
-4.6341%
APRI
1.61
-0.13
-7.47%
ARNA
4.49
+0.05
+1.13%
ATEC
1.41
+0.01
+0.71%
CNAT
6.66
-0.15
-2.20%
CRXM
0.354
-0.007
-1.8056%
CYTX
0.985
+0.002
+0.183%
DXCM
69.43
-1.13
-1.60%
GNMK
10.69
-0.24
-2.20%
HALO
16.86
-0.08
-0.50%
ILMN
189.59
-3.01
-1.56%
INNV
0.145
-0.008
-4.918%
INO
10.35
-0.25
-2.36%
ISCO
0.074
+0.004
+5.714%
ISIS
66.37
-1.38
-2.03%
LGND
89.75
+0.83
+0.93%
LPTN
2.23
-0.01
-0.45%
MBVX
3.36
-0.01
-0.30%
MEIP
2.16
-0.02
-0.92%
MNOV
4.09
+0.11
+2.76%
MRTX
27.87
-0.15
-0.54%
MSTX
0.49
0.00
+1.03%
NBIX
43.37
-0.31
-0.71%
NUVA
43.99
+0.23
+0.53%
ONCS
0.268
-0.009
-3.423%
ONVO
5.19
+0.12
+2.37%
OREX
7.36
-0.08
-1.08%
OTIC
31.8
-1.32
-3.99%
QDEL
23.38
-0.43
-1.81%
RCPT
169.885
-1.255
-0.733%
RGLS
17.49
-0.8
-4.37%
RMD
65.7
-7.68
-10.47%
SCIE
0.026
+0.002
+7.9167%
SPHS
0.8
-0.025
-3.0542%
SRNE
10.52
-0.15
-1.41%
TROV
8.8
-0.13
-1.46%
VICL
1.005
-0.025
-2.427%
VOLC
17.99
0.00
0.00%
ZGNX
1.54
-0.11
-6.67%
ACAD
38.36
-0.54
-1.39%
AEMD
0.196
-0.01
-4.6341%
APRI
1.61
-0.13
-7.47%
ARNA
4.49
+0.05
+1.13%
ATEC
1.41
+0.01
+0.71%
CNAT
6.66
-0.15
-2.20%
CRXM
0.354
-0.007
-1.8056%
CYTX
0.985
+0.002
+0.183%
DXCM
69.43
-1.13
-1.60%
GNMK
10.69
-0.24
-2.20%
HALO
16.86
-0.08
-0.50%
ILMN
189.59
-3.01
-1.56%
INNV
0.145
-0.008
-4.918%
INO
10.35
-0.25
-2.36%
ISCO
0.074
+0.004
+5.714%
ISIS
66.37
-1.38
-2.03%
LGND
89.75
+0.83
+0.93%
LPTN
2.23
-0.01
-0.45%
MBVX
3.36
-0.01
-0.30%
MEIP
2.16
-0.02
-0.92%
MNOV
4.09
+0.11
+2.76%
MRTX
27.87
-0.15
-0.54%
MSTX
0.49
0.00
+1.03%
NBIX
43.37
-0.31
-0.71%
NUVA
43.99
+0.23
+0.53%
ONCS
0.268
-0.009
-3.423%
ONVO
5.19
+0.12
+2.37%
OREX
7.36
-0.08
-1.08%
OTIC
31.8
-1.32
-3.99%
QDEL
23.38
-0.43
-1.81%
RCPT
169.885
-1.255
-0.733%
RGLS
17.49
-0.8
-4.37%
RMD
65.7
-7.68
-10.47%
SCIE
0.026
+0.002
+7.9167%
SPHS
0.8
-0.025
-3.0542%
SRNE
10.52
-0.15
-1.41%
TROV
8.8
-0.13
-1.46%
VICL
1.005
-0.025
-2.427%
VOLC
17.99
0.00
0.00%
ZGNX
1.54
-0.11
-6.67%
Home » Archive by Category

Syndication

Manufacturing Process Technician 1 – Illumina, Inc. – San Diego, CA

April 23, 2015 – 10:13 am

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. All About Us….
From Illumina, Inc. – 23 Apr 2015 17:13:33 GMT
– View all San Diego j…

Research Associate lll – Cytori Therapeutics – San Diego, CA

April 23, 2015 – 10:12 am

Degree with 3+ years experience in a biotech research environment. Maintaining compliance with established laboratory safety procedures as well as maintaining…
From Indeed – 23 Apr 2015 17:12:31 GMT
– View all San Diego jobs

Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results

April 23, 2015 – 10:00 am

Conference Call and Webcast Scheduled For Thursday, April 30, 2015

SAN DIEGO, April 23, 2015 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2015 results before the Nasdaq market opens on Thursday, April 30, 2015. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, April 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).

Participants can access the live conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company’s website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-839-5127 (US) or 402-220-2692 (International) using the conference ID: NBIX. The call will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.

 

SOURCE Neurocrine Biosciences, Inc.

Targazyme, Inc., Announces FDA Concurrence on Targazyme’s Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies

April 23, 2015 – 9:02 am

Targazyme, Inc., Announces FDA Concurrence on Targazyme’s Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies

Genome edit stops mitochondria disease

April 23, 2015 – 9:00 am

Selectively destroying damaged mitochondria leaves healthy ones to replicate.

Neuwrite SD: Am I addicted to coffee?

April 23, 2015 – 8:24 am

Recently over coffee, my friend told me that scientists have been doing drug research wrong for years. He was referring to an article about the effects of social environment on drug taking. In the article, the author criticizes scientists, government, …

Veracyte, Inc. Announces $40 Million Private Placement

April 23, 2015 – 6:00 am

SOUTH SAN FRANCISCO, Calif., April 23, 2015 /PRNewswire/ — Veracyte, Inc. (NASDAQ: VCYT) today announced that it has entered into a definitive agreement to sell approximately $40 million of its common stock in a private placement. Under the agreement, the investors will purchase an aggregate of 4,907,975 shares of common stock at a purchase price of $8.15 per share, the closing stock price on April 22, 2015. The private placement was led by new and existing investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners and venBio, among others. 

The private placement is expected to close on or about April 27, 2015, subject to the satisfaction of customary closing conditions. Veracyte intends to use the net proceeds from the placement to fund research and development, for product commercialization, and for working capital and general corporate purposes. Veracyte had $25.8 million in cash at March 31, 2015.

Piper Jaffray & Co. acted as sole lead placement agent and William Blair & Company, L.L.C. acted as a co-placement agent for the transaction.

The securities to be sold in the private placement have not been registered under the Securities Act of 1933 or applicable state securities laws and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from such registration requirements. Veracyte has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock sold in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Veracyte

Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 15,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. The Afirma test is recommended in leading practice guidelines and is covered for 145 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta™ Bronchial Genomic Classifier, a test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods and include, among others, statements we make regarding the anticipated gross proceeds from the transaction, the expected closing date of the transaction, the expected use of proceeds from the transaction, and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks related to whether Veracyte will be able to satisfy the conditions required to close the sale of the shares in the private placement and the fact that Veracyte’s management will have broad discretion in the use of the proceeds from any sale of the shares; the occurrence and outcome of clinical studies; the timing and publication of study results; the applicability of clinical results to actual outcomes; our inclusion in clinical practice guidelines; the continued application of clinical guidelines to our products; and other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.  

Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks or registered trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media: 
Tracy Morris 
650-380-4413 
tracy.morris@veracyte.com

Investors:
Pam Lord
Canale Communications
619-849-6003
pam@canalecomm.com

 

SOURCE Veracyte

Veracyte, Inc. Announces $40 Million Private Placement

April 23, 2015 – 6:00 am

SOUTH SAN FRANCISCO, Calif., April 23, 2015 /PRNewswire/ — Veracyte, Inc. (NASDAQ: VCYT) today announced that it has entered into a definitive agreement to sell approximately $40 million of its common stock in a private placement. Under the agreement, the investors will purchase an aggregate of 4,907,975 shares of common stock at a purchase price of $8.15 per share, the closing stock price on April 22, 2015. The private placement was led by new and existing investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners and venBio, among others. 

The private placement is expected to close on or about April 27, 2015, subject to the satisfaction of customary closing conditions. Veracyte intends to use the net proceeds from the placement to fund research and development, for product commercialization, and for working capital and general corporate purposes. Veracyte had $25.8 million in cash at March 31, 2015.

Piper Jaffray & Co. acted as sole lead placement agent and William Blair & Company, L.L.C. acted as a co-placement agent for the transaction.

The securities to be sold in the private placement have not been registered under the Securities Act of 1933 or applicable state securities laws and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from such registration requirements. Veracyte has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock sold in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Veracyte

Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 15,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. The Afirma test is recommended in leading practice guidelines and is covered for 145 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta™ Bronchial Genomic Classifier, a test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods and include, among others, statements we make regarding the anticipated gross proceeds from the transaction, the expected closing date of the transaction, the expected use of proceeds from the transaction, and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks related to whether Veracyte will be able to satisfy the conditions required to close the sale of the shares in the private placement and the fact that Veracyte’s management will have broad discretion in the use of the proceeds from any sale of the shares; the occurrence and outcome of clinical studies; the timing and publication of study results; the applicability of clinical results to actual outcomes; our inclusion in clinical practice guidelines; the continued application of clinical guidelines to our products; and other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.  

Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks or registered trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media: 
Tracy Morris 
650-380-4413 
tracy.morris@veracyte.com

Investors:
Pam Lord
Canale Communications
619-849-6003
pam@canalecomm.com

 

SOURCE Veracyte

Surfing into a Greener Future

April 23, 2015 – 6:00 am

UC San Diego’s efforts to produce innovative and sustainable solutions to the world’s environmental problems have resulted in a partnership with the region’s surfing industry to create the world’s first algae-based, sustainable surfboard.

Paralegal – ACADIA Pharmaceuticals Inc. – San Diego, CA

April 23, 2015 – 3:19 am

Knowledge of or experience in the Pharmaceutical or Biotech industry highly desired. Provides high level, confidential support to the legal department….
From ACADIA Pharmaceuticals Inc. – 23 Apr 2015 10:19:06 GMT
– View all S…